|Day Low/High||42.13 / 43.32|
|52 Wk Low/High||41.03 / 58.31|
Cardinal Health and McKesson have similar business models, but they are very different stocks.
Does it not make sense to create a separate portfolio made up of equities that will benefit -- as sick as that sounds -- when an area needs to rebuild?
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
Underwater positions on stocks you feel lukewarm about are prime candidates for tax selling.
CAH has managed to move above high volume resistance at the $54.50 level that has been a barrier since June.
These names combine good dividend yields with a track record of raising quarterly payouts.
Contrarians who bought several "dead men walking" retailers have pocketed big gains by defying conventional wisdom.
Buy Cardinal Health and give it time for the market to reassess the industry.
These stocks are selling at historically low earnings multiples, but have raised their dividends for decades.
Short-term pain should lead to long-term gains, especially for investors buying in now.
These 'bearish bets' show weak technical characteristics and have received recent quant downgrades.
Bitcoin, the bull market, and Amazon -- oh my! This is what you can't miss Wednesday.
The free market is going to take back control of interest rates.
The Saudi Arabian economy needs to rebalance away from oil.
I would look to begin trading it on the long side above $160.
News of acquisition hits this high-quality stock; here's your chance.
Here is a look at some stocks that are poised for excellent dividend returns in 2017.